Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3253036 | 0.96 | LMNA (0.59) | LMNANPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL1456221 | 0.81 | NNMT (0.46) | LMNANPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL13140612 | 0.81 | MAPT (0.49) | LMNANPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL29703893 | 0.81 | MAPT (0.62) | LMNANPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL1750160 | 0.81 | LMNA (0.45) | LMNANPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL29105359 | 0.81 | NPC1 (0.62) | LMNANPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL25591566 | 0.81 | MAPT (0.62) | LMNANPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL30661712 | 0.81 | NPC1 (0.62) | LMNANPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL2493590 | 0.81 | RAB9A (0.62) | NPC1RAB9ATP53SMN1; SMN2USP2 | |
| SCHEMBL1752793 | 0.80 | NPC1 (0.53) | LMNANPC1RAB9ATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110446706-A | (S)-[the fluoro- 5- of the chloro- 4- of 2- (7- morpholine -4- base quinazoline -4- base) phenyl] crystal form of-(6- methoxy-pyridazine -3- base) methanol | MERCK PATENT GMBH | 2019-11-12 | — | — | CN | claimed |
| CN-110446707-A | Pharmaceutical preparation | MERCK PATENT GMBH | 2019-11-12 | — | — | CN | claimed |
| US-20230183279-A1 | ORGANOMETALLIC COMPLEX, LIGHT EMITTING DIODE, AND ELECTRONIC DEVICE | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230183279-A1 | ORGANOMETALLIC COMPLEX, LIGHT EMITTING DIODE, AND ELECTRONIC DEVICE | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-06-15 | — | — | US | disclosed |
| CN-110446706-A | (S)-[the fluoro- 5- of the chloro- 4- of 2- (7- morpholine -4- base quinazoline -4- base) phenyl] crystal form of-(6- methoxy-pyridazine -3- base) methanol | MERCK PATENT GMBH | 2019-11-12 | — | — | CN | disclosed |
| CN-110446707-A | Pharmaceutical preparation | MERCK PATENT GMBH | 2019-11-12 | — | — | CN | disclosed |
| CN-110446705-A | Solid forms of (S) - [ 2-chloro-4-fluoro-5- (7-morpholin-4-ylquinazolin-4-yl) phenyl ] - (6-methoxy-pyridazin-3-yl) methanol | MERCK PATENT GMBH | 2019-11-12 | — | — | CN | disclosed |
| US-9663493-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663493-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9527819-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY | 2016-12-27 | — | — | US | disclosed |
| US-9527819-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY | 2016-12-27 | — | — | US | disclosed |
| WO-2007127475-A2 | PYRIDAZINES FOR DEMYELINATING DISEASES AND NEUROPATHIC PAIN | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127474-A2 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-23 | — | — | US | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| EP-1682519-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2006-07-26 | — | — | EP | disclosed |
| EP-1217001-B1 | QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | EISAI CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005049581-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALMIRALL PRODESFARMA, S.A. (ES) | 2005-06-02 | — | — | WO | disclosed |
| US-6599917-B1 | A squalene-synthesizing enzyme inhibitor, a cholesterol biosynthesis inhibitor and a triglyceride biosynthesis inhibitor | EISAI CO., LTD. (JP) | 2003-07-29 | — | — | US | disclosed |
| EP-1217001-A1 | QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Eisai Co., Ltd. (JP) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183279-A1 | ORGANOMETALLIC COMPLEX, LIGHT EMITTING DIODE, AND ELECTRONIC DEVICE | NR2E3, CRY1, GRK1 | LMNA 4753/4885NPC1 4328/4885RAB9A 2685/4885 |
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | PDE12, PDE4A, PDE7A | LMNA 4446/4885NPC1 3779/4885RAB9A 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.